Su Zhou Zelgen Biopharma Shares Rise 2% on Nov 12 Amid Strong Revenue Growth and ETF Gains
SuZhou Zelgen Biopharmaceutical’s latest trading surge—boosted by institutional inflows and a 4.05 % ETF lift—pairs a 54.49 % revenue rise with ongoing loss, spotlighting its recombinant protein & vaccine focus.
3 minutes to read